# Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma

> **NCT00960739** · PHASE2 · COMPLETED · sponsor: **Centre Oscar Lambret** · enrollment: 30 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Topotecan hydrochloride
- **PROCEDURE:** Autologous hematopoietic stem cell transplantation
- **RADIATION:** iobenguane I 131
- **RADIATION:** total-body irradiation

## Key facts

- **NCT ID:** NCT00960739
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2016-03
- **Final completion:** 2016-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-08-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00960739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00960739, "Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00960739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*